Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.
Fiche publication
Date publication
février 2019
Journal
Journal of gynecologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles, Pr GRAESSLIN Olivier
Tous les auteurs :
Reboux PA, Azaïs H, Canova CH, Bendifallah S, Ouldamer L, Raimond E, Hudry D, Coutant C, Graesslin O, Touboul C, Collinet P, Bricou A, Huchon C, Daraï E, Ballester M, Lévêque J, Lavoué V, Koskas M, Uzan C, Canlorbe G
Lien Pubmed
Résumé
According to recent European Society of Medical Oncology, European Society of Gynaecological Oncology and European Society of Radiotherapy and Oncology guidelines, adjuvant vaginal brachytherapy (VB) is optional in patients with intermediate risk (IR) and high-intermediate risk (HIR) endometrial cancer (EC). The aim of this French retrospective, multicenter study was to assess the impact of VB in these groups on local recurrence rate, local recurrence-free survival (RFS) and overall survival (OS).
Mots clés
Brachytherapy, Endometrial Cancer, Local Neoplasm Recurrence
Référence
J Gynecol Oncol. 2019 Feb 7;: